Dengue virus serotype 1-4 envelope protein (DENV E protein)

The Dengue virus envelope (E) protein is the primary structural component of the viral surface and plays a critical role in the viral life cycle by mediating host cell attachment and membrane fusion (UniProt P17763, P07564). It is organized as head-to-tail homodimers on the mature virion surface and undergoes a major conformational change from a dimer to a trimer under the acidic conditions of the host endosome to facilitate viral entry (PubMed: 15548633). As the principal target for neutralizing antibodies, the E protein is the central focus of vaccine development and therapeutic antibody design for all four Dengue serotypes (DENV 1-4). However, the protein is also associated with antibody-dependent enhancement (ADE), where non-neutralizing or sub-neutralizing antibodies against the E protein can facilitate viral entry into Fc-receptor-bearing cells, potentially leading to more severe clinical manifestations like Dengue Hemorrhagic Fever (Nature Reviews Microbiology: 10.1038/nrmicro3057). Current therapeutic strategies involve using chimeric viruses or recombinant subunits to elicit a balanced immune response against the E proteins of all four serotypes simultaneously (CDC, WHO).

Other names

Envelope glycoproteinE proteinDENV-1 EDENV-2 EDENV-3 EDENV-4 EDengue virus structural protein E

Vaccines utilize the E protein to induce neutralizing antibodies that block viral attachment and entry; monoclonal antibodies bind to specific epitopes on the E protein to prevent membrane fusion or receptor interaction.